EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Liver Cancer SUMMIT 20215-6 February 2021 Virtual Conference
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| P-001 | Surgery versus Sorafenib in case of BCLC-C hepatocellular carcinoma: an Italian weighted study | Simone Famularo |  Received |
 |
|||
| P-002 | Current Trends of Hepatocellular Carcinoma Characteristics in Greece | Georgios Markakis | Received |
|
|||
| P-003 | Patterns of response to atezolizumab (atezo) bevacizumab (bev) in hepatocellular carcinoma (HCC) from the Phase 1b GO30140 study | Stacey Stein | Received |
|
|||
| P-004 | Association between serum magnesium concentration and hepatocellular carcinoma in cirrhotic patients | Simona Parisse | Received |
|
|||
| P-005 | The best potential treatment for recurrent hepatocellular carcinoma after surgery: a machine learning predictive model for treatment allocation based on an Italian multicentric database | Francesca Carissimi | Received |
|
|||
| P-006 | Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids | Mikel Ruiz de Gauna | Received |
|
|||
| P-008 | Study on Regorafenib Combined with Transcatheter Arterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma after First Line Targeted Therapy | Haochen Wang | Received |
|
|||
| P-009 | Hepatocellular carcinoma prognostic scores: filling the gap? | Michele Campigotto | Received |
|
|||
| P-010 | A real-world evaluation of baseline characteristics, treatment patterns, and survival outcomes in patients with advanced hepatocellular carcinoma and elevated baseline alpha-fetoprotein levels receiving second-line therapy in the United States | Rajiv Ulpe | Received |
|
|||
| P-011 | Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: a new potential therapeutic target? | Alberto Zanetto | Received |
|
|||
| P-012 | Comparison of Sorafenib and Lenvatinib as first line therapy in Unresectable Hepatocarcinoma: a multi-center propensity score matching analysis | Margherita Rimini | Received |
|
|||
| P-013 | chronic hepatitis b under tenofovir or entecavir: performance of the page-b score to predict hepatocellular carcinoma | Daniela Falcão | Received |
|
|||
| P-014 | Diagnosing hepatocellular carcinoma are we getting it right first time? | Emma Saunsbury | Received |
|
|||
| P-015 | Modeling hepatocellular carcinoma cells dynamics by serological and imaging biomarkers in patients with response to sorafenib and/or regorafenib | Piero Colombatto | Received |
|
|||
| P-016 | Profiling of cell-free DNA using Whole-exome sequencing in patients with Hepatocellular carcinoma in Thailand | Pattapon Kunadirek | Received |
|
|||
| P-017 | Transcriptomic analyses reveal cancer-induce genes in PBMCs of Hepatocellular carcinoma for early diagnosis and prognosis | Pattapon Kunadirek | Received |
|
|||
| P-018 | Association between postoperative early recurrence of hepatocellular carcinoma and the expression pattern of circulating tumor cells in peripheral blood sample: a preliminary study. | Cristina Ciulli | Received |
|
|||
| P-019 | Circulating prostaglandin E2: a novel potential prognostic biomarker in patients with hepatocellular carcinoma | Filippo Pelizzaro | Received |
|
|||
| P-020 | Establishment of 3D-organoids from cryopreserved cancer tissues | Colin Rae | Received |
|
|||
| P-021 | Prognostic role of platelets-to lymphocytes ratio (PLR) and neutrophils-to-lymphocytes ratio (NLR) in hepatocellular carcinoma patients | Filippo Pelizzaro | Received |
|
|||
| P-022 | Impact of hospital volume on hepatocellular carcinoma survival in Italy | Filippo Pelizzaro | Received |
|
|||
| P-023 | Sarcomatoid hepatocellular carcinoma has distinct immunologic hallmarks from ordinary hepatocellular carcinoma | Ryo Morisue | Received |
|
|||
| P-024 | Characteristics of patients who received regorafenib for unresectable hepatocellular carcinoma in routine clinical practice: interim analysis of the prospective, observational REFINE study | OPEN Health | Received |
|
|||
| P-025 | Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2cm or smaller: a cohort study in Taiwan | Ching-Sheng Hsu | Received |
|
|||
| P-026 | Outcomes based on albumin-bilirubin grade in the phase 3 RESORCE trial of regorafenib versus placebo in patients with advanced hepatocellular carcinoma | OPEN Health | Received |
|
|||
| P-027 | Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma. | Petros Fessas | Received |
|
|||
| P-028 | Are undetected stones in the common biliary duct one of the causes of abscesses and bilomas development after percutaneous thermal ablation procedures? | Letizia Veronese | Received |
|
|||
| P-029 | Different modalities in management of bleeding related to post-banding ulcer following endoscopic variceal ligation in cirrhotic patients with or without hepatocellular Carcinoma | Mohamed Abdel-Samiee | Received |
|
|||
| P-030 | Copper chelators old drugs for new uses in the treatment of hepatocellular carcinoma | Silvano Junior Santini | Received |
|
|||
| P-031 | Diagnostic accuracy of a-fetoprotein (AFP), protein induced by vitamin K absence (PIVKA-II) and fibrogen like protein-2 (FGL-2) for HCC diagnosis among patients with liver cirrhosis | antonia syriha | Received |
|
|||
| P-032 | NADPH oxidase 4 (Nox4) deletion accelerates liver regeneration in mice | MACARENA HERRANZ ITÚRBIDE | Received |
|
|||
| P-033 | Development of ex vivo and in vivo tissue models of hepatocellular carcinoma and utility for immunotherapy investigations | Amy Collins | Received |
|
|||
| P-034 | Methylated Septin 9 (mSEPT9) as a biomarker for hepatocellular carcinoma. Results from University Hospital Coventry and Warwickshire NHS Trust, UK | Ayman Bannaga | Received |
|
|||
| P-036 | Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. | David Pinato | Received |
|
|||
| P-037 | PNPLA3 and Notch3 gene polymorphisms as risk factors for alcoholic cirrhosis development and its progression to hepatocellular carcinoma | Anna Mrzljak | Received |
|
|||
| P-038 | Urinary volatile organic compounds characterization in hepatocellular carcinoma pilot study | Ayman Bannaga | Received |
|
|||
| P-039 | Comparison of incidence and mortality risks due to acute kidney injury in hepatocellular carcinoma patients after liver resection, ablation, and transarterial chemoembolization: Meta-analysis of cohort studies | Boby Pratama Putra | Received |
|
|||
| P-040 | Predictive value of biomarkers a-fetoprotein (AFP) and fibrogen like protein-2 (FGL-2) for HCC among patients with liver cirrhosis | antonia syriha | Received |
|
|||
| P-041 | Transarterial chemoembolization: Predictors of liver function deterioration prior to hepatocellular carcinoma refractoriness | Joel Ferreira-Silva | Received |
|
|||
| P-042 | Two birds one stone: a case of synchronous hepatocellular carcinoma and intrahepatic cholangiocarcinoma | Catarina Félix | Received |
|
|||
| P-043 | Virtual biopsy for diagnosis of steatohepatitis and chemotherapy-associated liver injuries. A combined radiomic and clinical model. | Guido Costa | Received |
|
|||
| P-045 | Hepatic and extrahepatic colorectal metastases have discordant responses to systemic therapy. Pathology data from patients undergoing simultaneous resection of multiple tumor sites | Pio Corleone | Received |
|
|||
| P-046 | A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL. | Thomas Talbot | Received |
|
|||
| P-047 | Hsa-miR-21-5p disturbs the liver metabolic network in patients with NAFLD and is increased in NASH-associated HCC, contributing to hepatocarcinogenesis in mice | Pedro Rodrigues | Received |
|
|||
| P-048 | Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC. A single center retrospective case control study. | Bianca Rocco | Received |
|
|||
| P-049 | Perfusion analysis with dynamic contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma: a pilot study of a novel parameter aiming to improve the detection of wash-out | Lorenzo Mulazzani | Received |
|
|||
| P-050 | Chronic disruption of the late cholesterol synthesis leads to female-prevalent liver cancer | damjana rozman | Received |
|
|||
| P-052 | Human antigen R (HuR) SUMOylation is a fine-tuner of hepatocellular carcinoma (HCC) progression via the modulation of key mitochondrial mRNAs | Sofia Lachiondo-Ortega | Received |
|
|||
| P-053 | GALAD Score shows improved detection of early stage hepatocellular carcinoma in a Caucasian cohort of chronic Hepatitis B and C | Clemens Schotten | Received |
|
|||
| P-054 | Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice: CARDIO-SOR study. | Lorena Carballo-Folgoso | Received |
|
|||
| P-055 | Treatment of the chemotherapy induced hepatotoxicity | Mariia Zharova | Received |
|
|||
| P-056 | Serum miRNA profiling for the differential diagnosis of distal cholangiocarcinoma from pancreatic diseases | André L. Simão | Received |
|
|||
| P-057 | Hepatocellular Carcinoma Surveillance in Cirrhotic patients. | Shreyashee Sengupta | Received |
|
|||
| P-058 | Dynamic risk profile of hepatocellular carcinoma recurrence after curative intent liver resection | Tommy Ivanics | Received |
|
|||
| P-059 | Targeting tumor-initiating cells and compensatory YAP pathway activation to overcome sorafenib-induced resistance in hepatocellular carcinoma | Darko Castven | Received |
|
|||
| P-060 | Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients | Anthony Tan | Received |
|
|||
| P-061 | Circular RNA expression is modulated by RNA-binding proteins in hepatocellular carcinoma | Rok Razpotnik | Received |
|
|||
| P-062 | The impact of ultrasonographic blind spots for detecting early-stage hepatocellular carcinoma during surveillance | HA IL KIM | Received |
|
|||
| P-063 | Prognostic factors and post-treatment survival in patients enrolled onto second-line trials for unresectable hepatocellular carcinoma after sorafenib: a multicentre Italian cohort study | Nicola Personeni | Received |
|
|||
| P-064 | FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma unveil a necessary role for Erk signaling | Giulia Cristinziano | Received |
|
|||
| P-065 | Phase 1 study of autologous hepatitis B virus (HBV)-specific T cell receptor (TCR) T-cells, LioCyx-M in unresectable HBV-related hepatocellular carcinoma (HCC) | Regina Wong | Received |
|
|||
| P-066 | The combination of alcohol and metabolic syndrome is a fast track to hepatic tumorigenesis | Raquel Benedé-Ubieto | Received |
|
|||
| P-067 | Thyroid disease and hepatocellular carcinoma survival. A Danish nationwide cohort study | Linda Skibsted Kornerup | Received |
|
|||
| P-068 | Usefulness of circulating tumor cells in the management of patients with hepatocellular carcinoma | Elena Vargas Accarino | Received |
|
|||
| P-069 | Prognostic value of metabolic imaging data of C-choline PET/CT in patients undergoing hepatectomy for hepatocellular carcinoma | Jacopo Galvanin | Received |
|
|||
| P-070 | First real-life experience with atezolizumab plus bevacizumab in the treatment of advanced hepatocellular carcinoma | Martin Schnlein | Received |
|
|||
| P-071 | Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells | Alessandra Gentilini | Received |
|
|||
| P-072 | Alteration of miRNA content in extracellular vesicles in Sorafenib-treated liver cancer cells. miRNA prognostic value in plasma from patients with advanced HCC treated with Sorafenib | Patricia de la Cruz-Ojeda | Received |
|
|||
| P-073 | Virological and oncological factors of HCC recurrence after liver trasplantation in a single transplant center | Martina Gambato | Received |
|
|||
| P-074 | Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma | Claudia Campani | Received |
|
|||
| P-075 | Tumor Burden Score: a novel tool to predict immune-related liver injury during immunotherapy for hepatocellular carcinoma | Antonio DAlessio | Received |
|
|||
| P-076 | Phase 3 KEYNOTE-937 Trial: Adjuvant Pembrolizumab for Hepatocellular Carcinoma and Complete Radiologic Response After Surgical Resection or Local Ablation | Arndt Vogel | Received |
|
|||
| P-077 | PRPF8 regulates FAK/AKT pathway via fibronectin 1 splicing modulation to promote hepatocellular carcinoma aggressiveness | Juan Luis López-Cánovas | Received |
|
|||
| P-078 | Retrospective analysis of one-center experience in diagnosis and treatment of liver cancer | Mariia Zharova | Received |
|
|||
| P-079 | Analysis of risk factors associated with hepatocellular carcinoma development in patients with hepatitis B virus infection | Christos Triantos | Received |
|
|||
| P-081 | Validation of the aMAP risk score for the development of hepatocellular cancer in patients with cirrhosis in Glasgow | Chris Curran | Received |
|
|||
| P-082 | In vivo quantification of micro-balloon interventions (MBI) advantage. Cohort, retrospective, bi-centric study of DEB-TACE vs b-TACE and SIRT vs b-SIRT | Claudio Trobiani | Received |
|
|||
| P-083 | Comparison of Liver Transplant Criteria for Hepatocellular Carcinoma | Volkan &304;nce | Received |
|
|||
| P-084 | LDH as early prognostic markers for response in advanced hepatocellular carcinoma treated with Nivolumab | radu Pompilia | Received |
|
|||
| P-085 | DNA Methyltransferases as Potential Biomarkers for Egyptian Patients with HCV Related Hepatocellular Carcinoma | Mohamed Abdel-Samiee | Received |
|
|||
| P-086 | Survival analysis of the most frequent Single Nucleotide Variants in Hepatocellular Carcinoma | Jimmy A. Daza Barragan | Received |
|
|||
| P-087 | Se and Zn supplements attenuates HCC among recovered Hepatitis C Obese population in Middle Belt Nigeria. | OLAJUYIN OLALEYE | Received |
|
|||
| P-088 | CAMD score predicts the risk of hepatocellular carcinoma in Tunisian patients with chronic hepatitis B on antiviral therapy | Myriam Ayari | Received |
|
|||
| P-089 | Centrality of Estrogen Receptor 1 in Modulating Hepatocellular Carcinoma Progression through Wnt signaling | Elisa Pasini | Received |
|
|||
| P-090 | Hepatoprotective effects of pirfenidone in early stages of hepatocellular carcinoma | Jorge Silva-Gomez | Received |
|
|||
| P-091 | Real-world experience of hepatocellular carcinoma patients after sorafenib treatment: eligibility to subsequent lines and prognostic factors. | Leonardo Gomes da Fonseca | Received |
|
|||
| P-092 | Hepatotoxicity in patients with hepatocellular carcinoma on treatment with immune checkpoint inhibitors | Nicola Personeni | Received |
|
|||
| P-093 | Identification of a prognostic 3-protein score of childhood liver cancer by proteomic profiling | Juan Carrillo | Received |
|
|||
| P-094 | Pattern of macrovascular invasion in patients with hepatocellular carcinoma influences treatment and outcome. | Maria Guarino | Received |
|
|||
| P-095 | Title: Quantification of extracellular matrix features and its implications in hepatocellular carcinoma patients after curative liver resection | Kaiwen Huang | Received |
|
|||
| P-096 | Enhanced mitochondrial activity and immunometabolic reprogramming, by silencing Methylation Controlled J protein (MCJ), accelerates liver tumorigenesis in a hepatocellular carcinoma (HCC) mice model | Naroa Goikoetxea-Usandizaga | Received |
|
|||
| P-097 | Absence of a complete response after two trans-arterial chemo-embolizations during liver transplantation waiting list: should we persist or change? | Edoardo Poli | Received |
|
|||
| P-098 | Prediction of early recurrence of hepatocellular carcinoma after resection: international validation of the ERASL risk models | Berend Beumer | Received |
|
|||
| P-099 | Equal overall survival in elderly patients with hepatocellular carcinoma receiving palliative treatment | Thorben Frndt | Received |
|
|||
| P-100 | PD-1 expression, polymorphisms in PDCD1 and hepatocellular carcinoma (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). | HELEN REEVES | Received |
|
|||
| P-101 | Is first- and second-line immunotherapy sequence the optimal strategy for unresectable hepatocellular carcinoma? | Ciro Celsa | Received |
|
|||
| P-102 | Circulating miR 373 but not miR 210 as a new promising preoperative predictor of response to superive transarterial chemoembolization bridging therapy in Egyptian patients with hepatocellular carcinoma on top of hepatitis C virus infection | Omneya AbdelKarem | Received |
|
|||
| P-103 | Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients | Berend Beumer | Received |
|
|||
| P-105 | Endothelial Angiopoietin-2 overexpression in explanted HCCs identifies subjects at high risk of recurrence after liver transplant | Alessandra Pivetti | Received |
|
|||
| P-106 | Role of LI-RADS indeterminate observations in the prediction of HCC occurrence after direct antiviral therapy for hepatitis C virus infection. | Francesco Matteini | Received |
|
|||
| P-107 | lncRNA-H19 as a marker of liver disease progression: Hepatocellular Carcinoma | Ángela Rojas | Received |
|
|||
| P-108 | Nanobody-targeted liposomes for photodynamic therapy of Cholangiocarcinoma | Bárbara Mesquita | Received |
|
|||
| P-109 | Effectiveness of hepatocellular carcinoma treatments with curative intent: a nationwide study | Frederik Kraglund | Received |
|
|||
| P-110 | Epidemiological trends of hepatocellular carcinoma in patients with Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD) in Italy. | Monica Cucco | Received |
|
|||
| P-111 | An unexpected side effect of lenvatinib in patients treated for advanced hepatocellular carcinoma: increased hemoglobin level and erythrocytosis | Alina Pascale | Received |
|
|||
| P-112 | Are Radiology-based endpoints robust surrogate outcomes of overall survival in hepatocellular carcinoma patients treated with transarterial chemoembolization? | Ciro Celsa | Received |
|
|||
| P-113 | Vimentin expression in hepatocellular carcinoma relates with progenitor cells and epithelial-mesenchymal transition carcinogenesis | Joana Espírito Santo | Received |
|
|||
| P-114 | Inducing tissue-resident gamma delta T cells for immunotherapy of hepatocellular carcinoma | Nekisa Zakeri | Received |
|
|||
| P-115 | Nurse intervention optimizes the care of patients with hepatocellular carcinoma under systemic treatment | Gemma Iserte | Received |
|
|||
| P-116 | A CIRCULATING microRNAs SIGNATURE IDENTIFIES DAA-TREATED HCV-RELATED CIRRHOSIS PATIENTS AT HIGH RISK TO DEVELOP HCC | Massimo Levrero | Received |
|
|||
| P-117 | Cancer-associated pathways modulated by O-GlcNAc transferase and Enhancer of Zeste homolog 2 in hepatocellular carcinoma | Massimo Levrero | Received |
|
|||
| P-118 | Assessment of the impact of COVID-19 pandemic on Liver Cancer Management (CERO-19) | Sergio Munoz-Martínez | Received |
|
|||
| P-119 | Modified Page B Score Performance in Predicting HCC Risk in patients with chronic hepatitis B on antiviral therapy. | Fatma Ben Farhat | Received |
|
|||
| P-120 | CIRCULATING microRNAs PREDICT HEPATOCELLULAR CARCINOMA IN NUC-SUPPRESSED HBV CIRRHOTIC PATIENTS | Massimo Levrero | Received |
|
|||
| P-121 | Liver decompensation as late complication in HCC patients with long term response following ive internal radiation therapy. | Diederick van Doorn | Received |
|
|||
| P-122 | Prognostic performance of Toronto HCC risk index and the alpha-fetoprotein rate in patients with Hepatocellular carcinoma | Nouha Trad | Received |
|
|||
| P-123 | Safety and benefit of the combination of regorafenib and nivolumab in patients with hepatocellular carcinoma (HCC) in progression beyond two lines of oral chemotherapy | Ben merabet Yasmina | Received |
|
|||
| P-124 | Incidence of Hepatocellular Carcinoma in patients with Non-Alcoholic Fatty Liver Disease. A Systematic Review Meta-Analysis and Meta-Regression | Marco Sanduzzi Zamparelli | Received |
|
|||
| P-125 | Performance of ten non-invasive liver function tests in predicting one-year mortality in patients with hepatocellular carcinoma | Nouha Trad | Received |
|
|||
| P-126 | Impact of Hepatocellular Carcinoma screening in patients with Non-Achoholic Fatty Liver Disease and survival analyzis: a Brazilian Cross-Section Study | Regiane Saraiva de Souza Melo Alencar | Received |
|
|||
| P-127 | Whole-transcriptome profiling of biopsies from unresectable intrahepatic cholangiocarcinoma (iCCA) reveals a prognostic signature with treatment implications. | Massimiliano Salati | Received |
|
|||
| P-128 | Complete response after biological downstaging in patients with hepatocellular carcinoma: XXL-like prioritization for liver transplantation or waiting and see strategy? | Alessandro Vitale | Received |
|
|||
| P-129 | PSMA PET/CT imaging has equivalent performance to MRI for characterising hepatocellular carcinoma | Veronica Wong | Received |
|
|||
| P-130 | Stellate cell activation in liver cancer treatment | Xiaowen Liang | Received |
|
|||
| P-131 | Efficacy and safety of pemigatinib in European patients with previously treated locally advanced or metastatic cholangiocarcinoma: a FIGHT-202 subgroup analysis | Antoine Hollebecque | Received |
|
|||
Liver Cancer SUMMIT 2021
5-6 February 2021 Virtual Conference
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 11/01/2021 TO 05/02/2022
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
Poster submission deadline 01/02/2021
|
|
